Gregory C. Davis, Ph.D.
Greg Davis, PhD, began his professional career in 1980 with Monsanto Agricultural Products studying the effects of endogenous plant growth hormones on reproductive processes and yield. In 1985, Greg joined the Biotechnology Product Development Group in the Control Division of the Upjohn Company and was named Director of that group in 1987. In 1992, Greg moved to joined Eli Lilly, where he held various leadership positions over a 20 year career in Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. Greg retired from Eli Lilly in December 2012 as Executive Director and Senior Principle Fellow in Global Regulatory Affairs.
Greg has expertise in both the scientific and regulatory aspects of monoclonal antibody and biosimilars development. He has held various leadership positions on PhRMA committees, USP, BIO, and was the PhRMA liaison to the International Conference on Harmonization for Q5 (Biotechnology) topics for five years. In January of 2013, Greg founded Davis Consulting Services, a consultancy that works primarily with biopharmaceutical companies on CMC development issues and regulatory affairs. He also served from June 2014 to December 2015 as VP of Product Development at Calibrium, a biotech that was focused on new treatments for diabetes. Calibrium was purchased by Novo Nordisk in the fall of 2015. In June 2017 he joined Inotiv, a CRO providing pre-clinical and bioanalytical services to the pharmaceutical industry.
Greg is currently serving as Inotiv’s Chairman of the Board of Directors. In January of 2020, Greg joined MBXbio, a biotech company focused on rare endocrine disorders, as VP of Product Development.
Greg has expertise in both the scientific and regulatory aspects of monoclonal antibody and biosimilars development. He has held various leadership positions on PhRMA committees, USP, BIO, and was the PhRMA liaison to the International Conference on Harmonization for Q5 (Biotechnology) topics for five years. In January of 2013, Greg founded Davis Consulting Services, a consultancy that works primarily with biopharmaceutical companies on CMC development issues and regulatory affairs. He also served from June 2014 to December 2015 as VP of Product Development at Calibrium, a biotech that was focused on new treatments for diabetes. Calibrium was purchased by Novo Nordisk in the fall of 2015. In June 2017 he joined Inotiv, a CRO providing pre-clinical and bioanalytical services to the pharmaceutical industry.
Greg is currently serving as Inotiv’s Chairman of the Board of Directors. In January of 2020, Greg joined MBXbio, a biotech company focused on rare endocrine disorders, as VP of Product Development.